AbbVie has announced that the FDA has accepted for priority review its New Drug Application for upadacitinib for the treatment of rheumatoid arthritis (RA). Upadacitinib is a proposed once-daily, small-molecule, oral Janus kinase inhibitor that, if approved, could be an alternative to therapy with such injectable biologics as AbbVie’s flagship RA treatment, adalimumab (Humira), which will face biosimilar competition in the United States by 2023.
AbbVie has announced that the FDA has accepted for priority review its New Drug Application (NDA) for upadacitinib for the treatment of rheumatoid arthritis (RA). Upadacitinib is a proposed once-daily, small-molecule, oral Janus kinase (JAK) inhibitor that, if approved, could be an alternative to therapy with such injectable biologics as AbbVie’s flagship RA treatment, adalimumab (Humira), which will face biosimilar competition in the United States by 2023.
AbbVie has long reassured investors that upadacitinib will help the company continue to lead in the immunology market after biosimilars of adalimumab reach the United States. In a 2018 presentation, Richard Gonzalez, chairman of the board and chief executive officer of AbbVie, said that upadacitinib—which AbbVie expects to launch in 6 indications by 2022, beginning with RA in 2019—will help the company’s immunology leadership to “…evolve from a single product to a portfolio of therapies.”
The NDA for the drug is supported by data from 5 of the 6 phase 3 SELECT trials in RA, which cumulatively enrolled more than 4900 patients with moderate to severe RA.
In October 2018, results of the phase 3 SELECT-COMPARE trial, presented during the American College of Rheumatology’s 2018 annual meeting, showed that upadacitinib outperformed both placebo and adalimumab in treating RA.1 The study met its primary end points of noninferiority and superiority of upadacitinib versus adalimumab at week 12 and radiographic inhibition for upadacitinib versus placebo at week 26. In the trial, the proportion of patients with adverse events (AEs) was higher for those given upadacitinib than those given placebo, but similar to those given adalimumab.
However, a patient death in the phase 3 SELECT-MONOTHERAPY trial dampened some enthusiasm about the product; while the study met all of its primary and key secondary end points, 1 patient taking a 15-mg dose of the study drug had a fatal hemorrhagic stroke caused by a ruptured aneurysm. There was also 1 event of pulmonary embolism in the study, also in a patient taking a 15-mg dose.
JAK inhibitors have, as a class, come under some scrutiny for their potential for AEs; in April 2018, the FDA’s Arthritis Advisory Committee voted to recommend a low dose of Eli Lilly’s JAK inhibitor, baricitinib, but voted against recommending approval of a higher dose given concerns about the potential for dose-dependent AEs such as thrombosis.
AbbVie says that it anticipates an FDA decision on upadacitinib in the third quarter of 2019.
Reference
1. Fleischmann R, Pangan AL, Mysler E, et al. A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. Presented at: American College of Rheumatology 2018 Meeting; October 19-24, 2018; Chicago, Illinois. Abstract 890. acrabstracts.org/abstract/a-phase-3-randomized-double-blind-study-comparing-upadacitinib-to-placebo-and-to-adalimumab-in-patients-with-active-rheumatoid-arthritis-with-inadequate-response-to-methotrexate/.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.